ArticleFrontiers in bioengineering and biotechnology2026
Evaluation of DMSO-free cryopreservation reagent XT-Thrive for establishment of mesenchymal stem cell bank platform.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Effective cryopreservation is essential for the clinical application and large-scale banking of mesenchymal stem cells (MSCs). This study compares the performance of a novel DMSO-free cryoprotectant, XT-Thrive®, with a conventional DMSO-based solution, CryoStor® CS10, in preserving both commercial and donor-derived bone marrow MSCs (BM-MSCs). Evaluations focused on viability, recovery, proliferation, and functional characteristics across master cell bank (MCB), working cell bank (WCB), and final product (FP) stages. Methods: In Part 1, commercial BM-MSCs were cryopreserved in XT-Thrive or CS10 and evaluated for pre-freeze viability, post-thaw survival (up to 6 h), and recovery in 2D and 3D cultures. In Part 2, donor-derived BM-MSCs were cryopreserved at passages 2 (MCB), 4 (WCB), and 8 (FP), and assessed for cumulative population doubling levels (cPDL), immunophenotype, clonogenicity, differentiation potential, secretome profile, telomere length, karyotype stability, and tumorigenicity. Results: XT-Thrive-preserved MSCs maintained >90% pre-freeze viability after 24-h room temperature holding, compared to a ∼40% drop with CS10. Post-thaw viability at 6 h remained above 85% with XT-Thrive, vs. 60%-70% with CS10. In 3D microcarrier cultures under serum-free conditions, XT-Thrive-preserved MSCs demonstrated a ∼2.5-fold improvement in viable cell recovery compared to CS10, which failed to support recovery and expansion. XT-Thrive-preserved donor MSCs showed significantly higher cPDL at passages 8 FP (19.8 ± 0.4 vs. 15.4 ± 0.5, Conclusion: XT-Thrive provides superior pre-freeze stability, post-thaw recovery, expansion potential, and osteogenic functionality compared to CS10, while maintaining MSC identity and genomic stability. These results support XT-Thrive as a promising DMSO-free alternative for clinical-grade MSC biobanking and manufacturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.